{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:27:07Z","timestamp":1792272427855,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,3]]},"DOI":"10.7759\/cureus.22804","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T14:08:11Z","timestamp":1646316491000},"source":"Crossref","is-referenced-by-count":6,"title":["Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease?"],"prefix":"10.7759","author":[{"given":"Arimichi","family":"Kamata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Takasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies C","year":"2011","unstructured":"Davies C, Godwin J, Gray R, et al.. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011, 378:771-84. 10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3787","article-title":"Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials","volume":"26","author":"De Laurentiis M","year":"2008","unstructured":"De Laurentiis M, Cancello G, D'Agostino D, et al.. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008, 26:44-53. 10.1200\/JCO.2007.11.3787","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja L","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012, CD006243. 10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz G","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, et al.. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017, 377:122-31. 10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31914","article-title":"Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study","volume":"144","author":"van Maaren MC","year":"2019","unstructured":"van Maaren MC, de Munck L, Strobbe LJ, et al.. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019, 144:263-72. 10.1002\/ijc.31914","journal-title":"Int J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga J","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, et al.. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012, 366:109-19. 10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S26431","article-title":"Dormancy in breast cancer","volume":"4","author":"Banys M","year":"2012","unstructured":"Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H. Dormancy in breast cancer. Breast Cancer (Dove Med Press). 2012, 4:183-91. 10.2147\/BCTT.S26431","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4030\/jjcs.39.870","article-title":"Breast cancer recurrence as peritoneal metastasis 42 years after total mastectomy","volume":"39","author":"Takebayashi K","year":"2014","unstructured":"Takebayashi K, Kawai Y, Kitamura M, et al.. Breast cancer recurrence as peritoneal metastasis 42 years after total mastectomy. J Japanese Soc Surg. 2014, 39:870-3. 10.4030\/jjcs.39.870","journal-title":"J Japanese Soc Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies C","year":"2013","unstructured":"Davies C, Pan H, Godwin J, et al.. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013, 381:805-16. 10.1016\/S0140-6736(12)61963-1","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000353099","article-title":"Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer","volume":"85","author":"Nishimura R","year":"2013","unstructured":"Nishimura R, Osako T, Nishiyama Y, et al.. Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer. Oncology. 2013, 85:100-10. 10.1159\/000353099","journal-title":"Oncology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V","volume":"34","author":"Colleoni M","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN, et al.. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016, 34:927-35. 10.1200\/JCO.2015.62.3504","journal-title":"J Clin Oncol"},{"key":"ref12","unstructured":"Oxford English dictionary. (2022). Accessed. January 18, 2022: https:\/\/www.lexico.com\/en\/definition\/chronic."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27472","article-title":"Integrating a prospective surveillance model for rehabilitation into breast cancer survivorship care","volume":"118","author":"Gerber LH","year":"2012","unstructured":"Gerber LH, Stout NL, Schmitz KH, Stricker CT. Integrating a prospective surveillance model for rehabilitation into breast cancer survivorship care. Cancer. 2012, 118:2201-6. 10.1002\/cncr.27472","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510440047031","article-title":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators","volume":"271","year":"1994","unstructured":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994, 271.1587-92. 10.1001\/jama.1994.03510440047031","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.271.20.1593","article-title":"Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up","volume":"271","author":"Rosselli Del Turco M","year":"1994","unstructured":"Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994, 271:1593-7. 10.1001\/jama.271.20.1593","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000502636","article-title":"Metastatic breast cancer as a chronic disease: evidence-based data on a theoretical concept","volume":"15","author":"Elfgen C","year":"2020","unstructured":"Elfgen C, Montagna G, Schmid SM, Bierbauer W, G\u00fcth U. Metastatic breast cancer as a chronic disease: evidence-based data on a theoretical concept. Breast Care (Basel). 2020, 15:281-8. 10.1159\/000502636","journal-title":"Breast Care (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/82333-very-late-recurrence-in-breast-cancer-is-breast-cancer-a-chronic-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:24Z","timestamp":1707507444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/82333-very-late-recurrence-in-breast-cancer-is-breast-cancer-a-chronic-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.22804","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}